Rebecca Henderson - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Independent Director

Dr. Rebecca M. Henderson, Ph.D., is an Independent Director of Amgen Inc. Rebecca M. Henderson was the John and Natty McArthur University Professor at Harvard University since 2011. From 2009 to 2011, Dr. Henderson served as the Senator John Heinz Professor of Environmental Management at Harvard Business School. Prior to this, she was a professor of management at the Massachusetts Institute of Technology, or MIT, for 21 years, having been the Eastman Kodak LFM Professor of Management since 1999. Since 1995, she has also been a Research Associate at the National Bureau of Economic Research. She specializes in technology strategy and the broader strategic problems faced by companies in high technology industries. Dr. Henderson was a director of IDEXX Laboratories, Inc., a company which provides diagnostic and information technologybased products and services for veterinary, food and water applications, since 2003, chairing its Finance Committee and serving on its Nominating and Governance Committee. Dr. Henderson has also served as a director of the Ember Corporationrationration, a privatelyheld semiconductor chip manufacturer, and on its Compensation Committee, from 2001 to July 2009. She has further been a director of Linbeck Construction Corporationrationration, a privatelyheld facility solutions company, from 2000 until 2004. Dr. Henderson has published articles, papers and reviews in a range of scholarly journals
Age: 55  Director Since 2009  Ph.D    
805-447-1000  http://www.amgen.com
Henderson received an undergraduate degree from MIT and a doctorate from Harvard University.

Rebecca Henderson Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Lewis CampbellBristol Myers Squibb Company
2014
William MontagueEndo International plc
2009
Juan LucianoEli Lilly and Company
2016
Glenn TiltonAbbott Laboratories
2007
Robert MalchioneBio Rad Laboratories
2014
Anne WhitakerMallinckrodt Public Limited Com
2018
Katherine BaickerEli Lilly and Company
2011
Nancy HutsonEndo International plc
2009
Patricia RussoMerck Co
1995
Samuel ScottAbbott Laboratories
2007
Douglas IngramEndo International plc
2016
Ron TaylorAllergan plc
2013
Alan LacyBristol Myers Squibb Company
2008
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
James FarrellAbbott Laboratories
2006
JoAnn ReedMallinckrodt Public Limited Com
2013
Robert BertoliniBristol Myers Squibb Company
2017
Adriane BrownAllergan plc
2017
Jill SmithEndo International plc
N/A
Sally BlountAbbott Laboratories
2011
Thomas GlocerMerck Co
2007

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.